Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
Haohao Zhu, Hui Gao, Yingying Ji, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 129

Showing 1-25 of 129 citing articles:

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xin Xie, Tingting Yu, Xiang Li, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 137
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 110
The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study
Patricia LoRusso, Noboru Yamamoto, Manish R. Patel, et al.
Cancer Discovery (2023) Vol. 13, Iss. 8, pp. 1802-1813
Open Access | Times Cited: 51
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
Wei Wang, Najah Albadari, Yi Du, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 414-453
Open Access | Times Cited: 28
An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53
Yongmi Huang, Zhihao Jiao, Yuqing Fu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 265, pp. 116121-116121
Closed Access | Times Cited: 15
Pharmacological reactivation of p53 in the era of precision anticancer medicine
Amos Tuval, Charlotte Strandgren, Angelos Heldin, et al.
Nature Reviews Clinical Oncology (2023) Vol. 21, Iss. 2, pp. 106-120
Closed Access | Times Cited: 36
Small molecules targeting protein–protein interactions for cancer therapy
Defa Wu, Yang Li, Lang Zheng, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 10, pp. 4060-4088
Open Access | Times Cited: 31
Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells
Mikhail V. Blagosklonny
Oncotarget (2023) Vol. 14, Iss. 1, pp. 193-206
Open Access | Times Cited: 30
Explore drug-like space with deep generative models
Jianmin Wang, Jiashun Mao, Meng Wang, et al.
Methods (2023) Vol. 210, pp. 52-59
Closed Access | Times Cited: 22
Potential role of p53 deregulation in modulating immune responses in human malignancies: A paradigm to develop immunotherapy
Shivi Chauhan, Shivani Jaiswal, Vibhuti Jakhmola, et al.
Cancer Letters (2024) Vol. 588, pp. 216766-216766
Open Access | Times Cited: 11
p53/MDM2 signaling pathway in aging, senescence and tumorigenesis
Youyi Huang, Xiaofang Che, Peter Wang, et al.
Seminars in Cancer Biology (2024) Vol. 101, pp. 44-57
Closed Access | Times Cited: 10
Discovery of a Potent Dual Son of Sevenless 1 (SOS1) and Epidermal Growth Factor Receptor (EGFR) Inhibitor for the Treatment of Prostate Cancer
Lufeng Zheng, Yuxin Zhang, Shuang Mei, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 9, pp. 7130-7145
Closed Access | Times Cited: 9
Expanding the ligand spaces for E3 ligases for the design of protein degraders
Rahman Shah Zaib Saleem, Martin P. Schwalm, Stefan Knapp
Bioorganic & Medicinal Chemistry (2024) Vol. 105, pp. 117718-117718
Open Access | Times Cited: 7
Small-molecule correctors and stabilizers to target p53
Maryam M.J. Fallatah, Fiona V. Law, Warren Chow, et al.
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 5, pp. 274-289
Open Access | Times Cited: 20
p53 and Myofibroblast Apoptosis in Organ Fibrosis
Kealan McElhinney, Mustapha Irnaten, Colm O’Brien
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6737-6737
Open Access | Times Cited: 17
MDM2 Inhibition in the Treatment of Glioblastoma: From Concept to Clinical Investigation
Karolina Pellot, Julian S. Rechberger, Leo F. Nonnenbroich, et al.
Biomedicines (2023) Vol. 11, Iss. 7, pp. 1879-1879
Open Access | Times Cited: 15
The role of transcription factors in the crosstalk between cancer-associated fibroblasts and tumor cells
Xiaoyan Zhang, Meng Zhang, Hui Sun, et al.
Journal of Advanced Research (2024)
Open Access | Times Cited: 5
A self-amplifying loop of TP53INP1 and P53 drives oxidative stress-induced apoptosis of bone marrow mesenchymal stem cells
Fanchao Li, Fei Zhang, Tao Wang, et al.
APOPTOSIS (2024) Vol. 29, Iss. 5-6, pp. 882-897
Open Access | Times Cited: 5
TP53 mutations and MDM2 polymorphisms in breast and ovarian cancers: amelioration by drugs and natural compounds
Rituraj Chakraborty, Anupam Dutta, Rupak Mukhopadhyay
Clinical & Translational Oncology (2025)
Closed Access
Targeting Protein–Protein Interactions in Hematologic Malignancies
Tomasz Cierpicki, Jolanta Grembecka
Annual Review of Pathology Mechanisms of Disease (2025) Vol. 20, Iss. 1, pp. 275-301
Closed Access
Side-stepping the guardian of the genome: current cancer therapeutics targeting mutant p53
Iulianna C. Taritsa, Eric T. Fossel
Frontiers in Pharmacology (2025) Vol. 16
Open Access
The novel piperine derivative MHJ-LN inhibits breast cancer by inducing apoptosis via p53 activation
Hongyu Ren, Qi Gao, Mengmeng Wang, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
In silico Repurposing of FDA-Approved Drugs as Multi-target Inhibitors of Glioblastoma
Ridwan Abiodun Salaam, Funmilayo I. D. Afolayan, Damilare Adebayo Olaniyi, et al.
Scientific African (2025), pp. e02582-e02582
Open Access
Induction of the p21/CDK6 pathway and alteration of the immune microenvironment by the stem cell marker CBX3 in melanoma
Wanxian Chen, Linsa Zhou, Jingjing Jiang, et al.
Stem Cell Research & Therapy (2025) Vol. 16, Iss. 1
Open Access
ACSS3 promotes the tumorigenesis of non-small cell lung cancer via suppressing p53-mediated ferroptosis
Jing Zhang, Xiuhong Wang, Jingyi Wang, et al.
Experimental Cell Research (2025), pp. 114438-114438
Closed Access
Page 1 - Next Page

Scroll to top